TrialSignal
Clinical trial intelligence report
A Prospective Single-arm Single-center Clinical Study：Assessment of the Safety and Effects of Stereotactic Ablation Radiotherapy (SABR) Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer (sMPLC)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT04840758
Status
UNKNOWN
Phase
PHASE1
Sponsor
The First Affiliated Hospital of Xiamen University
Executive brief
Investment-Ready Snapshot
The purpose of this study is to assess of the Safety and Effects of Stereotactic Ablation Radiotherapy (SABR) combined with Sintilimab in early inoperable synchronous Multiple Primary Lung Cancer (sMPLC)
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04840758
Indication
Multiple Primary Lung Cancer
Modality
monoclonal antibody
Target
Stereotactic Ablation Radiotherapy, Sintilimab
Intervention
Stereotactic Ablation Radiotherapy, Sintilimab
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.